Blue Water Biotech Inc

Blue Water Biotech Inc., a biopharmaceutical company headquartered in Cincinnati, Ohio, is dedicated to creating groundbreaking therapies for global health issues. The company is a publicly traded entity listed on the Nasdaq stock exchange under the ticker symbol BWV. With a team of three employees, Blue Water Biotech harnesses the power of proprietary technology originating from prestigious institutions such as the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. Blue Water Biotech's core focus lies in developing innovative vaccines to combat a range of infectious diseases. They are pioneering a universal flu vaccine designed to offer protection against all dangerous strains. Furthermore, the company has licensed a cutting-edge norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from CCHMC. This platform holds immense potential for developing vaccines against various infectious diseases, including norovirus/rotavirus and malaria. In addition to these initiatives, Blue Water Biotech is actively researching a Streptococcus pneumoniae (pneumococcus) vaccine candidate aimed at preventing acute otitis media (AOM), a prevalent and highly contagious middle ear infection in children. Blue Water Biotech distinguishes itself through its commitment to leveraging advanced scientific research and collaborations with leading medical institutions. This collaborative approach allows them to develop innovative vaccine solutions that address critical global health challenges. To learn more about Blue Water Biotech Inc. and its groundbreaking vaccine development efforts, please visit their website at bwbioinc.com.